Intriguingly, CD19 chimeric antigen receptor T-cell therapy possesses high effectiveness when treating B-cell lymphoma or B-cell acute lymphoblastic leukemia, which provides patients who had no response to conventional therapy with an alternative therapeutic option, and it can greatly improve patient prognosis, which makes it a promising therapeutic option (Xu et al., 2019). The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.